

Mengtao Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9217403/publications.pdf>

Version: 2024-02-01

177
papers

3,102
citations

236925

25
h-index

254184

43
g-index

188
all docs

188
docs citations

188
times ranked

3622
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region. <i>Arthritis Care and Research</i> , 2022, 74, 187-198.	3.4	25
2	SMO3, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2022, 61, 1841-1848.	1.9	3
3	Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study. <i>Clinical Rheumatology</i> , 2022, 41, 731-739.	2.2	2
4	Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study. <i>Lupus Science and Medicine</i> , 2022, 9, e000617.	2.7	8
5	The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV). <i>Clinical Rheumatology</i> , 2022, 41, 1371-1379.	2.2	3
6	Characteristics and risk factors of retinal vasculopathy in antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 178-186.	1.6	1
7	Detection of IgA Antiphospholipid Antibodies Does not Improve Thrombotic Antiphospholipid Syndrome Classification: A two-Center Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210811.	1.7	3
8	Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1052-1054.	0.9	1
9	Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review. <i>Lupus Science and Medicine</i> , 2022, 9, e000636.	2.7	2
10	The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. <i>Cancer Communications</i> , 2022, 42, 435-446.	9.2	22
11	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
12	Clinical characteristics of axial spondyloarthritis patients in China: results from ChinaSpA, the Chinese Spondyloarthritis Registry. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 544-550.	0.8	5
13	Pilot study of baricitinib for active Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1050-1052.	0.9	9
14	Primary Sjogren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 103084.	5.8	25
15	A 16-year-old boy with arthritis, rash, and hemoptysis: Beyond undifferentiated connective tissue disease. <i>Rheumatology and Immunology Research</i> , 2022, 3, 46-50.	0.8	0
16	The challenges and future perspective for the management of systemic lupus erythematosus in China: A concise annual report of 2020. <i>Rheumatology and Immunology Research</i> , 2022, 3, 38-44.	0.8	2
17	Effects of conventional rehabilitative and aerobic training in patients with idiopathic inflammatory myopathy. <i>Rheumatology and Immunology Research</i> , 2022, 3, 23-30.	0.8	1
18	Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study. <i>Lupus</i> , 2022, 31, 885-890.	1.6	3

#	ARTICLE	IF	CITATIONS
19	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future. , 2022, 239, 108192.		7
20	Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. <i>Rheumatology</i> , 2022, 62, 256-263.	1.9	11
21	Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	1
22	Structural and Functional Characterization of Gray Matter Alterations in Female Patients With Neuropsychiatric Systemic Lupus. <i>Frontiers in Neuroscience</i> , 2022, 16, 839194.	2.8	1
23	Clinical characteristics and outcomes of lupus myocarditis: a retrospective case control study in Chinese patients. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
24	Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210973.	2.5	2
25	Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 982-990.	1.9	7
26	Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. <i>Rheumatology</i> , 2021, 60, 2629-2634.	1.9	15
27	The PD-1/PD-L pathway in rheumatic diseases. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 48-59.	1.7	26
28	Musculoskeletal ultrasound imaging training, use, and knowledge among rheumatologists in China. <i>Clinical Rheumatology</i> , 2021, 40, 321-330.	2.2	7
29	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. <i>International Journal of Clinical Practice</i> , 2021, 75, e13819.	1.7	1
30	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.9	160
31	Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis. <i>Clinical Rheumatology</i> , 2021, 40, 1819-1826.	2.2	5
32	Multimodal photoacoustic/ultrasonic imaging system: a promising imaging method for the evaluation of disease activity in rheumatoid arthritis. <i>European Radiology</i> , 2021, 31, 3542-3552.	4.5	17
33	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 2472-2477.	1.9	20
34	Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102691.	5.8	38
35	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 111-118.	1.2	22
36	Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	2.2	10

#	ARTICLE	IF	CITATIONS
37	Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842199808.	2.1	4
38	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 21.	3.5	14
39	Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis. <i>Frontiers in Medicine</i> , 2021, 8, 630660.	2.6	1
40	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. <i>Frontiers in Immunology</i> , 2021, 12, 580271.	4.8	3
41	Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 152.	2.7	8
42	The current status and challenges in the diagnosis and treatment of rheumatoid arthritis in China: An annual report of 2019. <i>Rheumatology and Immunology Research</i> , 2021, 2, 49-56.	0.8	8
43	Activation of Toll-Like Receptor 7 Signaling Pathway in Primary Sjögren's Syndrome-Associated Thrombocytopenia. <i>Frontiers in Immunology</i> , 2021, 12, 637659.	4.8	10
44	Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2021, 8, 618486.	2.6	3
45	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <i>Lancet Rheumatology</i> , The, 2021, 3, e517-e531.	3.9	26
46	Chinese SLE Treatment and Research group (CSTAR) registry 2009–2019: Major clinical characteristics of Chinese patients with systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2021, 2, 43-47.	0.8	10
47	Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody. <i>BMC Pulmonary Medicine</i> , 2021, 21, 88.	2.0	16
48	2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 1-14.	0.8	9
49	Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT. <i>Arthritis Research and Therapy</i> , 2021, 23, 127.	3.5	13
50	Establishing a Risk Prediction Model for Atherosclerosis in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 622216.	4.8	11
51	Interventricular systolic asynchrony predicts prognosis in patients with systemic sclerosis-associated pulmonary arterial hypertension. <i>Rheumatology</i> , 2021, , .	1.9	3
52	Immunoglobulin G4-Related Disease Accompanied by Primary Myelofibrosis: Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 638794.	2.6	1
53	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 880-895.	1.9	11
54	Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CRDC-MYO Registry. <i>Clinical Rheumatology</i> , 2021, 40, 4597-4608.	2.2	10

#	ARTICLE	IF	CITATIONS
55	Three new inflammatory markers C reactive protein to albumin ratio, neutrophil to lymphocyte ratio, and platelet to lymphocyte ratio correlated with relapsing polychondritis disease activity index. <i>Clinical Rheumatology</i> , 2021, 40, 4685-4691.	2.2	11
56	Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 669137.	4.8	16
57	Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study. <i>Lupus</i> , 2021, 30, 1459-1468.	1.6	8
58	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. <i>Clinical Rheumatology</i> , 2021, 40, 4589-4596.	2.2	4
59	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. <i>Rheumatology and Immunology Research</i> , 2021, 2, 63-78.	0.8	0
60	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. <i>Pulmonary Circulation</i> , 2021, 11, 1-8.	1.7	1
61	Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 648881.	4.8	9
62	Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1847-1855.	5.6	18
63	Clinical Characteristics and Prognoses of Patients With Systemic Lupus Erythematosus Hospitalized for Pulmonary Infections. <i>Frontiers in Medicine</i> , 2021, 8, 732681.	2.6	3
64	Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 741369.	4.8	10
65	Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 20.	3.5	1
66	Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis. <i>Rheumatology</i> , 2021, 60, e227-e228.	1.9	28
67	Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232098705.	2.5	5
68	Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232097699.	2.5	12
69	A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110486.	2.5	2
70	Thrombocytopenia Is an Independent Risk Factor for the Prognosis of Thrombotic Microangiopathy in Chinese Patients With Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021, 8, 772607.	2.6	1
71	Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 21, 102996.	5.8	1
72	The LPS induced pyroptosis exacerbates BMP2 signaling deficiency to potentiate SLE-associated PAH. <i>FASEB Journal</i> , 2021, 35, e22044.	0.5	15

#	ARTICLE	IF	CITATIONS
73	Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies. <i>Frontiers in Immunology</i> , 2021, 12, 783616.	4.8	10
74	Lupus gut microbiota transplants cause autoimmunity and inflammation. <i>Clinical Immunology</i> , 2021, 233, 108892.	3.2	25
75	Long-term outcomes of patients with systemic lupus erythematosus: A Multicenter Cohort Study from CSTAR registry. <i>Rheumatology and Immunology Research</i> , 2021, 2, 195-202.	0.8	7
76	Clinical characteristics of axial spondyloarthritis patients in China: results from ChinaSpA, the Chinese Spondyloarthritis Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
77	Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: A Retrospective Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 791348.	4.8	39
78	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	1.9	27
79	The Chinese herb <i>Tripterygium wilfordii</i> Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center. <i>Clinical Rheumatology</i> , 2020, 39, 813-821.	2.2	8
80	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020, 157, 955-965.	0.8	26
81	Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2095333.	2.7	23
82	Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-ups and predictors of achieving treatment target. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1719-1727.	1.9	3
83	Prevalence, predictors and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: a systematic review. <i>Arthritis Care and Research</i> , 2020, , .	3.4	7
84	Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 339.	1.7	1
85	Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition). <i>Annals of Translational Medicine</i> , 2020, 8, 1213-1213.	1.7	73
86	Factors Associated With Renal Involvement in Primary Sjögren's Syndrome: A Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 614482.	2.6	5
87	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. <i>Hypertension</i> , 2020, 76, 1161-1168.	2.7	8
88	Clinical features and long-term outcomes of Chinese patients with scleroderma renal crisis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1194-1200.	1.9	3
89	Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population. <i>Frontiers in Immunology</i> , 2020, 11, 568503.	4.8	9
90	Aberrant expression of cell-free nucleosomes in dermatomyositis/polymyositis. <i>Dermatologic Therapy</i> , 2020, 33, e14460.	1.7	3

#	ARTICLE	IF	CITATIONS
91	Development and formulation of the classification criteria for osteoarthritis. <i>Annals of Translational Medicine</i> , 2020, 8, 1068-1068.	1.7	3
92	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	3.5	20
93	P157 Update on the real-time collecting system data of SLE treatment and research group (CSTAR) registry: clinical features and remission of patients with systemic lupus erythematosus in China. , 2020, , .		0
94	O27 Development and validation of a multivariable model for 5-year survival in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. , 2020, , .		0
95	O28 Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a single-center cohort study. , 2020, , .		3
96	P10 Antiphospholipid antibodies associated extra-criteria clinical manifestations should not be ignored. , 2020, , .		0
97	P11 Early efficient anticoagulation improves the long-term prognosis in patients with antiphospholipid syndrome associated portal vein thrombosis. , 2020, , .		0
98	Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab. <i>Lupus</i> , 2020, 29, 1961-1967.	1.6	7
99	Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e036748.	1.9	11
100	Association between acute phase reactants, interleukin-6, tumor necrosis factor- α , and disease activity in Takayasu's arteritis patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 285.	3.5	16
101	Comparison of Clinical Features in HLA-B27 Positive and Negative Patients With Axial Spondyloarthritis: Results From a Cohort of 4,131 Patients. <i>Frontiers in Medicine</i> , 2020, 7, 609562.	2.6	13
102	Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points. <i>Frontiers in Pharmacology</i> , 2020, 11, 606497.	3.5	2
103	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
104	Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	2.2	5
105	Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 717-722.	1.9	21
106	Association between comorbidities and extraglandular manifestations in primary Sjögren's syndrome: a multicenter cross-sectional study. <i>Clinical Rheumatology</i> , 2020, 39, 2677-2688.	2.2	13
107	JAK Inhibitors: Prospects in Connective Tissue Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 334-351.	6.5	83
108	Tofacitinib in patients with refractory Takayasu's arteritis. <i>Rheumatology</i> , 2020, 59, e95-e98.	1.9	26

#	ARTICLE	IF	CITATIONS
109	<p>Satisfaction of Patients and Physicians with Treatments for Rheumatoid Arthritis: A Population-Based Survey in China</p>. Patient Preference and Adherence, 2020, Volume 14, 1037-1047.	1.8	8
110	Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China. European Respiratory Journal, 2020, 56, 1902157.	6.7	27
111	Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial. BioDrugs, 2020, 34, 381-393.	4.6	21
112	Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. Lupus, 2020, 29, 795-803.	1.6	22
113	Assessment of lung glucose uptake in patients with systemic lupus erythematosus pulmonary arterial hypertension: a quantitative FDG-PET imaging study. Annals of Nuclear Medicine, 2020, 34, 407-414.	2.2	11
114	2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. Rheumatology and Immunology Research, 2020, 1, 5-23.	0.8	24
115	Characteristics and long-term outcomes of patients with lupus-related protein-losing enteropathy: A retrospective study. Rheumatology and Immunology Research, 2020, 1, 47-52.	0.8	2
116	Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. Medicine (United States), 2020, 99, e23184.	1.0	5
117	Aberrant glycosylation in autoimmune disease. Clinical and Experimental Rheumatology, 2020, 38, 767-775.	0.8	7
118	Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a case control study. Clinical and Experimental Rheumatology, 2020, 38, 940-948.	0.8	2
119	Gut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosus. Molecular Medicine, 2019, 25, 35.	4.4	85
120	Identification of 6 dermatomyositis subgroups using principal component analysis-based cluster analysis. International Journal of Rheumatic Diseases, 2019, 22, 1383-1392.	1.9	5
121	High TLR7 Expression Drives the Expansion of CD19+CD24hiCD38hi Transitional B Cells and Autoantibody Production in SLE Patients. Frontiers in Immunology, 2019, 10, 1243.	4.8	49
122	Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Annals of the Rheumatic Diseases, 2019, 78, 1441-1443.	0.9	43
123	Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2019, 38, 2181-2187.	2.2	21
124	Gastrointestinal manifestations on impaired quality of life in systemic sclerosis. Journal of Digestive Diseases, 2019, 20, 256-261.	1.5	12
125	Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors. International Journal of Rheumatic Diseases, 2019, 22, 921-928.	1.9	26
126	AB0387–...SATISFACTION OF PATIENTS AND PHYSICIANS WITH TREATMENTS FOR RHEUMATOID ARTHRITIS: A NATIONWIDE SURVEY IN CHINA. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
127	220â€¦Clinical characteristics and remission of patients with systemic lupus erythematosus in china: results from SLE treatment and research group (CSTAR) registry with a real-time collecting system. , 2019, , .		3
128	247â€¦New organ involvement development during follow-up of patients with systemic lupus erythematosus in China: a Multi-center cohort study from CSTAR registry. , 2019, , .		0
129	33â€¦Composite goals plus inflammation: further risk assessment for systemic lupus erythematosus associated pulmonary arterial hypertension in CSTAR-PAH cohort. , 2019, , .		0
130	Risk factors for progression of carotid intima-media thickness in patients with systemic lupus erythematosus: protocol for an observational cohort study in China. <i>BMJ Open</i> , 2019, 9, e030721.	1.9	0
131	Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogrenâ€™s syndrome: a retrospective cohort study. <i>Clinical Rheumatology</i> , 2019, 38, 477-485.	2.2	10
132	Inflammation in SLE-PAH: good news or not?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e135-e135.	0.9	10
133	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. <i>European Respiratory Journal</i> , 2019, 53, 1800081.	6.7	49
134	Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2019, 38, 727-738.	2.2	50
135	Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. <i>Heart Lung and Circulation</i> , 2019, 28, 1655-1663.	0.4	9
136	Cysteine-rich protein 61 as a novel biomarker in systemic lupus erythematosus-associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 623-632.	0.8	5
137	CD146: a potential therapeutic target for systemic sclerosis. <i>Protein and Cell</i> , 2018, 9, 1050-1054.	11.0	9
138	Characteristics and risk factors of pulmonary arterial hypertension in patients with primary SjÃ¶gren's syndrome. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1068-1075.	1.9	21
139	Chinese SLE Treatment and Research Group (CSTAR) registry:VIII. Influence of socioeconomic and geographical variables on disease phenotype and activity in Chinese patients with <sc>SLE</sc>. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 716-724.	1.9	13
140	Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products. <i>MAbs</i> , 2018, 10, 166-176.	5.2	20
141	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 979-985.	2.2	19
142	Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. <i>Arthritis Research and Therapy</i> , 2018, 20, 235.	3.5	32
143	High levels of circulating cellâ€free <sc>DNA</sc> are a biomarker of active <sc>SLE</sc>. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13015.	3.4	45
144	Is it possible to apply the treat-to-target strategy in primary SjÃ¶grenâ€™s syndrome-associated pulmonary arterial hypertension?. <i>Clinical Rheumatology</i> , 2018, 37, 2989-2998.	2.2	5

#	ARTICLE	IF	CITATIONS
145	The renal artery is involved in Chinese Takayasu's arteritis patients. <i>Kidney International</i> , 2018, 93, 245-251.	5.2	24
146	Chinese lupus treatment and research group (CSTAR) registry: X. family history in relation to lupus clinical and immunological manifestations. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 81-87.	0.8	1
147	Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 836-840.	0.8	20
148	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. <i>International Journal of Cardiology</i> , 2017, 236, 432-437.	1.7	81
149	Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study. <i>Clinical Rheumatology</i> , 2017, 36, 2727-2732.	2.2	9
150	Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2017, 44, 1867-1874.	2.0	30
151	Response to letter "Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: Methodological issues" <i>International Journal of Cardiology</i> , 2017, 249, 418.	1.7	1
152	The clinical characteristics of Chinese Takayasu's arteritis patients: a retrospective study of 411 patients over 24 years. <i>Arthritis Research and Therapy</i> , 2017, 19, 107.	3.5	41
153	Chinese Registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 251.	3.5	68
154	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE. <i>Scientific Reports</i> , 2017, 7, 7617.	3.3	10
155	The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 171-175.	0.8	13
156	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
157	Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. <i>Medicine (United States)</i> , 2016, 95, e2761.	1.0	59
158	The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. <i>Scientific Reports</i> , 2016, 6, 38687.	3.3	20
159	Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. <i>Clinical Drug Investigation</i> , 2016, 36, 889-902.	2.2	6
160	The Role of Anti-U1 RNP Positivity in Predicting Survival in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Angel or Demon? Comment on the Article by Sobanski et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1788-1789.	5.6	8
161	Clinical Features, Morbidity, and Risk Factors of Intestinal Pseudo-obstruction in Systemic Lupus Erythematosus: A Retrospective Case-control Study. <i>Journal of Rheumatology</i> , 2016, 43, 559-564.	2.0	22
162	Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 250-257.	5.8	45

#	ARTICLE	IF	CITATIONS
163	Intracardiac thrombus in patients with Behcet's disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience. <i>Clinical Rheumatology</i> , 2016, 35, 2501-2507.	2.2	23
164	The 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Could Classify Systemic Sclerosis Patients at Earlier Stage: Data from a Chinese EUSTAR Center. <i>PLoS ONE</i> , 2016, 11, e0166629.	2.5	7
165	Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S26-S33.	0.8	1
166	Predictors of health-related quality of life in patients with systemic lupus erythematosus associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 291-5.	0.8	7
167	Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2015, 67, 2394-2402.	5.6	34
168	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0134451.	2.5	21
169	Clinical characteristics of immunoglobulin G-related disease: a prospective study of 118 Chinese patients. <i>Rheumatology</i> , 2015, 54, 1982-1990.	1.9	185
170	CRDC: a Chinese rheumatology research platform. <i>Clinical Rheumatology</i> , 2015, 34, 1347-1352.	2.2	20
171	Related factors of fetal loss in Chinese women with systemic lupus erythematosus: data from Chinese SLE Treatment and Research Group registry IV. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 654-660.	1.9	13
172	Applications of Next-generation Sequencing in Systemic Autoimmune Diseases. <i>Genomics, Proteomics and Bioinformatics</i> , 2015, 13, 242-249.	6.9	26
173	Chinese SLE Treatment and Research Group Registry: III. Association of Autoantibodies with Clinical Manifestations in Chinese Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	2.2	40
174	Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years. <i>Clinical Rheumatology</i> , 2014, 33, 57-63.	2.2	98
175	Lupus nephritis associated with placental site trophoblastic tumor: A case report and review of the literature. <i>Gynecologic Oncology Case Reports</i> , 2014, 9, 26-28.	0.9	6
176	Correlation of Th17 cells and CD4 ⁺ CD25 ⁺ regulatory T cells with clinical parameters in patients with systemic sclerosis. <i>Chinese Medical Journal</i> , 2014, 127, 3557-61.	2.3	15
177	Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus—a prospective pilot study. <i>Rheumatology</i> , 2011, 50, 1640-1644.	1.9	50